The NFkappaB pathway and endocrine-resistant breast cancer.
about
GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerRegulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifenCarcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 miceRedox Regulation in Cancer Stem CellsPhytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancersGemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cellsGenomic alterations in breast cancer patients in betel quid and non betel quid chewersKnockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin PathwayErlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRIEnhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancerExpression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells.Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.The relationship between members of the canonical NF-κB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancerLRP16 integrates into NF-κB transcriptional complex and is required for its functional activation.A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.Alpha-actinin 4 and tumorigenesis of breast cancer.Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cellsPositive cross-talk between estrogen receptor and NF-kappaB in breast cancer.Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters.Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancerEstradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB binding to ST8SIA1 promoter.Transcription factor Ets1 cooperates with estrogen receptor α to stimulate estradiol-dependent growth in breast cancer cells and tumors.Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cellsNFkappaB1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NFkappaB2/p52 and RelB.Human esophageal myofibroblasts secrete proinflammatory cytokines in response to acid and Toll-like receptor 4 ligands.A role for estrogen receptor phosphorylation in the resistance to tamoxifen.Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription ProfilingNovel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets DeterminationAtaxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression.Singleminded-2s (Sim2s) promotes delayed involution of the mouse mammary gland through suppression of Stat3 and NFκBCXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signallingNF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPTCyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cellsExposure to ionizing radiation induced persistent gene expression changes in mouse mammary glandInhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).The interaction between ER and NFκB in resistance to endocrine therapy.The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer.The immune system and inflammation in breast cancer.Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinomaRole of NF-κB as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian Patients
P2860
Q21560759-E9BB5EE7-C4BC-4B91-B3A6-1780D11986AEQ24632895-73EFA5C7-01DA-47E3-973B-5ECEA934F98CQ24707869-521C9BD7-8E5E-484A-AE7A-A3FF9C876319Q26798198-67FCA36E-C981-4133-A334-9DAFC66F6764Q26798324-7668B1C1-33DF-4DAC-9943-8A91ED1C288BQ28297927-BC318951-704B-4F11-91EE-6EC9C3B3491DQ28482521-1FCB3B42-F424-434A-8F82-888DE7B9C61CQ28555056-AF1CA62E-AD08-40F0-99C9-5A2607679264Q30828291-DE7D88D1-E85A-488A-A05B-6BAF885426BBQ33281087-EC50A9D8-C5B6-48EB-AB25-02916A0C1CE1Q33609716-68D43F17-9A23-4A74-9B76-A383D7F08DF7Q33656026-C7382CFA-74DD-4798-A049-BEF6FFEB5D0DQ33779333-931D6F94-99F4-400F-9D8E-81544B3530CFQ33869694-A7D3E104-7864-4093-882C-280CB9D19756Q34029272-57542E06-734E-45A2-BBA6-69CC27B2F93BQ34084701-092A5B96-68CA-4296-82F9-01EB0E1D78A1Q34367908-AAF1A64E-8755-4183-A268-BB8B17AEAB58Q34374852-B2451590-5135-4AAE-A74C-0D0FA56999D3Q34393481-FADC7A9D-EAC8-48AF-90CC-D6B9F874F1E1Q34442193-67777250-E04F-4D6E-9949-4A8E3E9E1C02Q34693290-BE61F32D-857F-49B0-AC8F-B1FD737026ADQ34851281-97452553-A97D-408A-AF01-24E98416E6E3Q35011812-03460A00-C19A-412F-89AF-3CE8EFA749C5Q35241505-4EB21C59-D5C6-4DCA-B69F-3FA7A3AAF11FQ35671825-C8F396A8-BD55-4FDF-9D2E-7A0A0000D7FCQ35684445-42B728F3-E0F0-4B0A-B3CE-44F861B015A7Q35799611-5BF0A9B7-C591-4697-9E36-DF6177367096Q35996034-D786EDA5-6FDA-406E-AF85-B35150E37BA2Q36003028-4A66D023-E99D-4552-8182-E6BAB45FA147Q36067460-F6D1F78A-9E79-4906-B571-17189D9A8D63Q36075168-5D4A667D-0FA0-4A62-A9AA-485DDFA0E7CAQ36347158-91594A78-EAE0-4552-9A5B-1504783621EDQ36451013-AD4F03F5-B50A-4B88-A0AC-0A12D24FEEABQ36552489-C39919BB-AB7A-425A-B648-FE17E3096C72Q36799721-8D319DEE-8C6D-4B5B-890C-734D7D655DCFQ36924406-5BE163D9-7309-4583-95A3-F2E14AAECB1FQ36935954-AF0F1EB4-67CE-4735-B493-4BBBFBD5C4BFQ37033451-191F60D3-72F0-4CD3-A384-A45886C6BE14Q37151107-8E3114A1-339F-498B-B6E4-E1B216ECF331Q37165541-CA06C82F-17D2-40AB-A3F8-8E446466692C
P2860
The NFkappaB pathway and endocrine-resistant breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The NFkappaB pathway and endocrine-resistant breast cancer.
@ast
The NFkappaB pathway and endocrine-resistant breast cancer.
@en
type
label
The NFkappaB pathway and endocrine-resistant breast cancer.
@ast
The NFkappaB pathway and endocrine-resistant breast cancer.
@en
prefLabel
The NFkappaB pathway and endocrine-resistant breast cancer.
@ast
The NFkappaB pathway and endocrine-resistant breast cancer.
@en
P2093
P356
P1476
The NFkappaB pathway and endocrine-resistant breast cancer.
@en
P2093
Eppenberger U
Eppenberger-Castori S
P304
P356
10.1677/ERC.1.00977
P478
12 Suppl 1
P577
2005-07-01T00:00:00Z